ReviewLife (Basel, Switzerland)2021
Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The silent catecholamine: a rapidly evolving, exclusively dopamine-secreting pheochromocytoma in a 22-year-old.JCEM case reports · 2026Article
- Biomarkers of metastatic disease in pheochromocytoma and paraganglioma.Endocrine connections · 2026Article
- Predictive Factors of Malignancy in Cervical Paragangliomas: A Retrospective Study.Head & neck · 2025Article
- Prediction of Metastasis in Paragangliomas and Pheochromocytomas Using Machine Learning Models: Explainability Challenges.Sensors (Basel, Switzerland) · 2025Article
- Article
- Clinicopathological data and the role of miRNA expression in patients with pheochromocytomas/paragangliomas.Frontiers in endocrinology · 2025Article
- Non-Susceptibility Gene Variants in Head and Neck Paragangliomas.International journal of molecular sciences · 2024Article
- Intratumoral Microbiome in Head and Neck Paragangliomas.International journal of molecular sciences · 2024Article
- Genetic changes in theFrontiers in endocrinology · 2024Article
- Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.Cancer medicine · 2023Review
- Comprehensive Genetic Study of Malignant Cervical Paraganglioma.International journal of molecular sciences · 2023Article
- TheInternational journal of molecular sciences · 2022Article
- [Pheochromocytoma and paraganglioma during childhood and adolescence].Radiologie (Heidelberg, Germany) · 2022Review
- Editorial: High-Throughput Sequencing-Based Investigation of Chronic Disease Markers and Mechanisms.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Paragangliomas and pheochromocytomas (PPGLs) are rare neuroendocrine tumors originating from paraganglionic tissue in many sites of the body. Most PPGLs are characterized by nonaggressive behavior but all of them have the potential to metastasize. PPGLs represent a great diagnostic dilemma as it is difficult to recognize tumors that are likely to be metastasizing; criteria of malignancy can be found both in benign and metastatic forms. This review aims to analyze the current knowledge of the nature of metastasizing PPGLs paying particular attention to head and neck paragangliomas (HNPGLs). Potential predictors of the malignancy risk for PPGLs were summarized and discussed. These data may also help in the development of diagnostic and prognostic strategies, as well as in the identification of novel potential therapeutic targets for patients with PPGLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.